Cargando…

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient

Vitiligo is an autoimmune skin disease presenting with areas of depigmentation. Recent reports suggest that Janus kinase (JAK) inhibitors may be an effective therapy. In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo, fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berbert Ferreira, Sineida, Berbert Ferreira, Rachel, Neves Neto, Afonso Cesar, Assef, Silvana Martins Caparroz, Scheinberg, Morton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488419/ https://www.ncbi.nlm.nih.gov/pubmed/34703426 http://dx.doi.org/10.1159/000513938

Ejemplares similares

Topical tofacitinib in treatment of alopecia areata
por: Ferreira, Sineida Berbert, et al.
Publicado: (2020)

Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
por: Ferreira, Sineida Berbert, et al.
Publicado: (2016)

Atopic dermatitis: Tofacitinib, an option for refractory disease
por: Berbert Ferreira, Sineida, et al.
Publicado: (2020)

An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
por: Berbert Ferreira, Rachel, et al.
Publicado: (2019)

Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
por: Scheinberg, Morton, et al.
Publicado: (2017)

Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
por: Narla, Shanthi, et al.
Publicado: (2020)

Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib
por: Kim, Sa Rang, et al.
Publicado: (2021)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2020)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
por: Gaber, Timo, et al.
Publicado: (2020)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
por: Abdou, Asmaa Gaber, et al.
Publicado: (2018)

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
por: Kim, Sa Rang, et al.
Publicado: (2018)

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
por: Gwak, Eun Hye, et al.
Publicado: (2020)

Microscopic Colitis with Escitalopram Use and New Onset Vitiligo
por: Iqbal, Humzah, et al.
Publicado: (2022)

Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation()()
por: Komnitski, Melpone, et al.
Publicado: (2020)

Porphyria Cutanea Tarda Presenting with Scleroderma, Ichthyosis, Alopecia, and Vitiligo
por: MacGillivray, Megan E., et al.
Publicado: (2018)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
por: Todberg, Tanja, et al.
Publicado: (2020)

A Case Report of Vitiligo Induced by Alexandrite Hair Removal Laser
por: Alkhalifah, Azzam
Publicado: (2021)

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
por: Samaka, Rehab M, et al.
Publicado: (2019)

Bullous Pemphigoid in Which Eruption Developed Exclusively on Preexisting Eruption of Vitiligo Vulgaris
por: Oka, Masahiro, et al.
Publicado: (2020)

Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
por: Alatabani, Maram, et al.
Publicado: (2021)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
por: Talty, Ronan, et al.
Publicado: (2021)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
por: Giordano, Domenico, et al.
Publicado: (2021)

Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib
por: Moore, Angela Yen, et al.
Publicado: (2022)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
por: Aleisa, Ahmad I., et al.
Publicado: (2020)

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
por: Hasni, Sarfaraz A., et al.
Publicado: (2021)

Further comment on articles pertaining to: “Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19”
por: Berbert, Anne
Publicado: (2021)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5i7tug4g4t4tbsr50tk3jsl0hs